Thirty patients who had previously had an atherothrombotic stroke received mesoglycan 50 mg BID for 3 months to evaluate the effect of the drug on plasma fibrinogen levels, antithrombin III concentration, and other coagulative parameters. After 7 days of treatment, mesoglycan significantly decreased plasma fibrinogen levels (P <0.05). This result was confirmed after 30 and 90 days (P <0.005 and P <0.001, respectively). No statistically significant changes in antithrombin III, prothrombin time, partial thromboplastin time, or platelet count were observed with respect to baseline values. No side effects were reported. Our results suggest that mesoglycan can effectively reduce plasma fibrinogen levels without interfering with other coagulative parameters.
ASJC Scopus subject areas